Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).

Nicola S CurryCanan AlbayrakMiguel A EscobarPål Andre HolmeSusan KearneyRobert KlamrothMudi MisgavClaude NégrierAllison WheelerElena SantagostinoMidori ShimaAndrea LandorphSidsel Marie TønderSteven R Lentz

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)

Weekly N8-GP was well tolerated and efficacious and may benefit selected "low bleeder" patients with haemophilia A.

Keyphrases

phase iii
open label
clinical trial
double blind
placebo controlled
phase ii
early onset
study protocol
randomized controlled trial
drug induced